Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4379 - "Effect of Neoadjuvant Chemotherapy on Disease Free Survival and Over all Survival in Triple-Negative Breast Cancer Patients"


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Breast Cancer


Jasneet Gill


Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


J. Gill1, A.N. Mishra2

Author affiliations

  • 1 Medical Oncology, Gandhi Medical College, 462001 - Bhopal/IN
  • 2 Surgical Oncology, Gandhi Medical College, 462001 - Bhopal/IN


Abstract 4379


Breast cancer (BC) is the most common cancer in India with 150000 new cases are diagnosed and 70000 women dies of it every year. Triple-negative breast cancer (TNBC) is an aggressive subtype that lack ER and PR expression and absence of overexpressed or amplified HER2. TNBC accounts for 15%-25% of all invasive BC, occurs more in younger women and is associated with higher histologic grade and advanced disease. Our goal was to study the relation between triple-negative receptor status and major determinants of clinical outcome, such as response to neoadjuvant chemotherapy (rate of pathologic complete response [pCR]), progression free survival (PFS), site-specific distribution of recurrence, postrecurrence survival (PRS) and overall survival (OS).


We included 2658 patients who received neoadjuvant chemotherapy at Jawaharlal Nehru Cancer Hospital Bhopal for stage I-III breast cancer from 1990 to 2010 and for whom complete receptor information were available. Clinical and pathologic parameters, pCR, survival measurements and organ-specific relapse rates were compared between patients with TNBC and non-TNBC.


505 patients (19%) had TNBC. Mean age for TNBC (42 years) was lesser than non-TNBC (56 years; P=.002). Patients with TNBC had significantly higher pCR rates (34% v 14%; P=.028) but decreased 5 year PFS rates (P


TNBC patients have increased pCR rates (excellent survival) compared with non-TNBC. However TNBC patients with RD have significantly worse survival after neoadjuvant chemotherapy in first 5 years.TNBC patients may be best treated with 3rd generation adjuvant or neoadjuvant chemotherapy regimens that achieve the highest possible pCR rates. With high risk of distant metastases, these patients require closer surveillance in initial years of follow-up.

Clinical trial identification


Legal entity responsible for the study

Jawaharlal Nehru Cancer Hospital, Bhopal, India




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.